Lipocine Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LPCN$1.71+5.6%Stored close · as of Nov 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| License revenue | $109,987 | $500,000 |
| Minimum guaranteed royalties revenue (reversal of variable consideration) | (2,960,805) | - |
| Total revenues (reversal of variable consideration), net | (2,850,818) | 500,000 |
| Operating expenses: | ||
| Research and development | 10,175,251 | 8,556,888 |
| General and administrative | 4,904,888 | 4,062,487 |
| Total operating expenses | 15,080,139 | 12,619,375 |
| Operating loss | (17,930,957) | (12,119,375) |
| Other income (expense): | ||
| Interest and investment income | 1,366,940 | 572,578 |
| Interest expense | - | (27,098) |
| Unrealized gain on warrant liability | 212,690 | 565,940 |
| Gain on litigation settlement liability | - | 250,000 |
| Total other income, net | 1,579,630 | 1,361,420 |
| Loss before income tax expense | (16,351,327) | (10,757,955) |
| Income tax expense | (755) | (681) |
| Net loss | (16,352,082) | (10,758,636) |
| Issuance of Series B preferred stock dividend | (89) | - |
| Net loss attributable to common shareholders Net loss attributable to common shareholders | $(16,352,171) | $(10,758,636) |
| Basic loss per share attributable to common stock | $(3.10) | $(2.06) |
| Weighted average common shares outstanding, basic | 5,269,671 | 5,231,681 |
| Diluted loss per share attributable to common stock | $(3.14) | $(2.15) |
| Weighted average common shares outstanding, diluted | 5,269,671 | 5,256,169 |
| Comprehensive loss: | ||
| Net loss | $(16,352,082) | $(10,758,636) |
| Net unrealized gain (loss) on available-for-sale securities | 27,580 | (2,305) |
| Comprehensive loss | $(16,324,502) | $(10,760,941) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.